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OBJECTIVES The purpose of this study is to determine whether lipoprotein(a) (Lp[a]) is an independent
risk factor for coronary spasm and occurrence of acute myocardial infarction (AMI) in
patients with coronary spasm.
BACKGROUND Although elevated serum Lp(a) levels are known to be associated with coronary atheroscle-
rosis and AMI, the association between the elevated level of this lipoprotein and coronary
spasm remains to be elucidated.
METHODS Serum Lp(a) levels were measured using a latex immunoassay in 77 patients with coronary
spasm but without a significant (.75%) fixed coronary stenosis, including 16 with prior
myocardial infarction (MI), in 177 patients with a fixed stenosis but without rest angina,
including 114 with prior MI and in 81 control subjects without coronary artery disease.
RESULTS The serum Lp(a) level in patients with coronary spasm (median; 17 mg/dl) was higher (p ,
0.01) than in control subjects (12 mg/dl) but lower (p , 0.01) than in patients with a fixed
stenosis (23 mg/dl). The incidence of subjects with higher (.25 mg/dl) serum Lp(a) levels
was higher in patients with a fixed stenosis (46%, p , 0.01) but not in patients with coronary
spasm (27%), compared with control subjects (21%). Among the patients with coronary
spasm, the incidence of higher Lp(a) levels was higher in patients with than in those without
a history of prior MI (56% vs. 21%, p , 0.05). The patients with higher Lp(a) levels had a
higher incidence of prior MI than those without (41% vs. 13%, p , 0.05). The multivariate
analysis confirmed that higher serum Lp(a) level is an independent determinant for prior MI
in these patients (odds ratio, 4.19; 95%, confidence interval, 1.03 to 17.00).
CONCLUSIONS Elevated serum level of Lp(a) was found to be associated with a history of prior MI in patients
with coronary spasm, suggesting that Lp(a) may play an important role in the genesis of
thrombotic coronary occlusion and the occurrence of AMI subsequent to coronary spasm. (J
Am Coll Cardiol 2000;35:1200–5) © 2000 by the American College of Cardiology
Coronary artery spasm plays an important role in the entire
spectrum of acute ischemic events, although the exact
pathophysiologic mechanisms by which coronary artery
spasm is triggered remain to be elucidated (1,2). Coronary
spasm can be the primary event in the pathophysiology of
acute myocardial infarction (AMI) (3,4). Thrombin activa-
tion and fibrin formation have been shown to be induced by
coronary spasm (5,6). Also, impaired fibrinolytic activity,
which is lowest in the early morning, was reported in
patients with variant angina (7). These reports suggest that
coronary spasm may trigger thrombus formation in coronary
arteries and that the reduction of fibrinolytic activity may
slow the removal of thrombus, ultimately leading to AMI in
some patients. However, differences in the prevalence of risk
factors or predisposing conditions between subjects with
coronary spasm who develop and those who do not develop
AMI are unknown, whereas both a high incidence of
current smoking and a lower level of serum high-density
lipoprotein (HDL) cholesterol without an elevation of
low-density lipoprotein (LDL) cholesterol level have been
identified in patients with coronary vasospasm (8–13).
Intracoronary thrombus formation has been thought to
play an important role in the genesis of AMI (14). A
number of recent studies have shown that increased plasma
concentrations of lipoprotein(a) (Lp[a]) are associated with
coronary atherosclerosis and also the evolution of AMI
(15–17). This lipoprotein has been suggested to be an
independent risk factor for the development of cardiovas-
cular and cerebrovascular diseases (17,18). Lipoprotein(a)
consists of an LDL bound by a disulfide bond to apoli-
poprotein(a) (apo[a]). Apolipoprotein(a) is a hydrophilic
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glycoprotein of the plasminogen family. It acts as a com-
petitive inhibitor of the tissue-type plasminogen activator
(t-PA) and inhibits the generation of thrombolytic enzyme
plasmin because of its structural similarity to plasminogen
(19). These unique features give Lp(a) potential atherogenic
and thrombogenic roles, and they have generated consider-
able interest in this lipoprotein. However, the possible
significance of Lp(a) in patients with coronary vasospasm
has not been clarified.
The purpose of this study is to determine whether the
elevation of serum Lp(a) levels is a risk factor for coronary
spasm and also whether it is a risk factor for the develop-
ment of AMI in patients with coronary spasm.
METHODS
Study patients. Seventy-seven consecutive patients (65
men and 12 women: mean age 57 6 11 years; range, 15 to
74 years) with coronary spastic angina but without signifi-
cant (.75% of luminal diameter) organic coronary arterial
stenosis (Spasm group), in whom electrocardiographic ST-
segment shift was confirmed during attacks occurring spon-
taneously, were studied for the determination of serum level
of Lp(a). In all the patients, coronary artery spasm was
angiographically demonstrated in at least one of the major
coronary arteries during spontaneous or induced attacks by
intracoronary injection of acetylcholine (20–22). Another
177 patients (142 men and 35 women: mean age, 61 6 9
years; range, 36 to 82 years) with a significant organic
narrowing of either coronary artery documented by coronary
angiographic study, who had abnormal treadmill exercise
stress test results but no rest angina (Stenosis group), were
also subjected to the study. Coronary artery stenosis was
quantitated with a computer-assisted analysis system. For
the control group, 81 age- and sex-matched subjects (65
men and 16 women: mean age, 57 6 12 years; range, 26 to
73 years) without any significant systemic disease, who had
normal treadmill exercise stress test results with the standard
Bruce protocol (Control group), were selected. No patient
was receiving estrogen therapy. Clinical and angiographic
characteristics of the study groups are listed in Table 1. A
history of previous myocardial infarction (MI) had been
diagnosed based on typical chest pain lasting for more than
30 min with ST-T segment deviation on a standard 12-lead
electrocardiogram and an increase in creatine kinase to at
least twice the normal upper limit. Written informed
consent was obtained from all the study patients, and the
study protocol followed the guidelines of the ethics com-
mittee at our institution.
Serum analysis. Venous samples were obtained in the
fasting state when the subjects were free of any acute illness.
Samples were not obtained within four weeks of the onset of
AMI (23). The total cholesterol level was measured directly
in the serum, and HDL cholesterol was measured after
precipitation of very-low-density lipoprotein cholesterol and
LDL cholesterol with dextran sulfate-magnesium chloride
by an enzymatic method. The concentration of triglyceride
in serum was determined by measuring glycerol after an
enzymatic hydrolysis with lipase-esterase. The LDL-
cholesterol concentration was calculated according to the
following formula: LDL cholesterol 5 (total cholesterol) 2
(HDL cholesterol) 2 (triglyceride/5). Lipoprotein(a) was
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
apo(a) 5 apolipoprotein(a)
HDL 5 high-density lipoprotein
LDL 5 low-density lipoprotein
Lp(a) 5 lipoprotein(a)
MI 5 myocardial infarction
PAI 5 plasminogen activator inhibitor
t-PA 5 tissue-type plasminogen activator
Table 1. Clinical and Angiographic Characteristics of the Study Groups
Characteristic Control Spasm Stenosis
No. of patients 81 77 177
Age 57 6 12 57 6 11 61 6 9
Male/female 65/16 65/12 142/35
Previous myocardial infarction 0 (0%) 16 (21%)† 114 (64%)*
Smoking 48 (59%) 65 (84%)† 126 (71%)
Hypertension 11 (14%) 31 (40%)† 85 (48%)†
Hypercholesterolemia (.220 mg/dl) 15 (19%) 15 (19%) 51 (29%)
Diabetes mellitus 0 (0%) 13 (17%)† 69 (39%)*
Body mass index .25 15 (19%) 18 (23%) 34 (19%)
Coronary organic stenosis
0-vessel — 77 (100%) 0 (0%)
1-vessel — 0 (0%) 88 (50%)
2-vessel — 0 (0%) 60 (34%)
3-vessel — 0 (0%) 29 (16%)
*p , 0.01 vs. control and spasm. †p , 0.01 vs. control.
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measured by the method of latex-enhanced turbidimetric
immunoassay (24).
Assessment of coronary risk factors. Smoking was con-
sidered to be present if the patient had smoked more than
three cigarettes a day for at least one year. Diabetes mellitus
was diagnosed either clinically or by a 75-g oral glucose
tolerance test according to World Health Organization
criteria (25). Hypertension was defined as a persistent
resting blood pressure exceeding 140 mm Hg (systolic) or
90 mm Hg (diastolic). Body mass index was calculated as
weight (kg)/height (cm)2.
Statistical analysis. Baseline characteristics of the study
patients were compared using the chi-square test. Lipopro-
tein(a) data were expressed as medians (interquartile or 25th
to 75th percentile range) because of the known skewed
distribution of these levels. Other data are presented as
mean 6 standard deviation. The Mann-Whitney U test was
used for two-group comparison of Lp(a). An overall test for
differences among the three groups was performed using the
Kruskall-Wallis test. Comparisons of serum lipid levels and
age among the three groups were performed with one-way
analysis of variance followed by Scheffe´’s test. To determine
whether serum Lp(a) level is an independent risk factor for
AMI in patients with coronary vasospasm, multivariate
logistic regression analyses were performed using software
(SPSS Professional Statistics 7.5 for Windows; SPSS Japan
Inc.). The dependent variable was a history of previous MI.
The results of the multivariate analysis are expressed as odds
ratios for the comparison of risk between the 10% and 90%
percentiles (with 95% confidence intervals). The level of
significance was set as p , 0.05.
RESULTS
Clinical variables in study patients. The baseline charac-
teristics, including conventional coronary risk factors and
coronary arteriographic findings in study patients, are
shown in Table 1. Smoking, hypertension and diabetes
mellitus were all significantly more prevalent in the Spasm
group than in the Control group. Both a history of previous
MI and diabetes mellitus were significantly less prevalent in
the Spasm group than in the Stenosis group, although no
significant differences were found in the incidence of other
conventional risk factors. No significant differences were
noted in the incidence of hypercholesterolemia among the
groups, although 22% of the Stenosis group were receiving
lipid-lowering treatment.
Lp(a) levels in study patients. Serum Lp(a) concentrations
in the study patients are summarized in Table 2 and Figure
1. The serum Lp(a) level was significantly (p , 0.01) higher
in the Stenosis group (median: 23 mg/dl) than in either the
Control group (12 mg/dl) or the Spasm group (17 mg/dl).
The incidence of patients with serum Lp(a) levels higher
than 25 mg/dl was significantly (p , 0.01) greater in the
Stenosis group (46%) than in either the Control group
(21%) or the Spasm group (27%). As a whole, the serum
Lp(a) level was significantly (p , 0.01) higher in the Spasm
group than in the Control group. However, the incidence of
higher (.25 mg/dl) serum Lp(a) level in the Spasm group
was not significantly different from that in the Control
group. In the 51 patients in the Spasm group with a fixed
stenosis below 50%, both the serum Lp(a) level (16 mg/dl)
and the incidence of higher serum Lp(a) level (25%) were
not significantly different from those in the Control group.
The comparative data of the incidence of various risk
factors between the patients with, and those without, prior
MI in the Spasm group are shown in Table 3. In the Spasm
group, there were no significant differences in the incidence
of smoking, hypertension, hypercholesterolemia, diabetes
mellitus and obesity between the patients with, and those
without, prior MI. However, the serum level of Lp(a) was
significantly higher in those patients with than in those
without prior MI (29 vs. 16 mg/dl, p , 0.05) (Figure 2). By
contrast, the serum level of Lp(a) was comparable—not
significantly different—between the patients with, and
those without, prior MI in the Stenosis group (Figure 3).
The incidence of prior MI was compared between the
Table 2. Serum Lipoprotein(a) Levels and Incidence of
Lipoprotein(a) Levels .25 mg/dl in Study Patients
n Lp(a)* (mg/dl) Lp(a) >25 mg/dl
Control 81 12 (6–22) 17 (21%)
Spasm 77 17 (11–29)† 21 (27%)
Stenosis 177 23 (12–44)‡ 81 (46%)‡
*Median (interquartile range).
†p , 0.01 vs. control.
‡p , 0.01 vs. control and spasm.
Lp(a) 5 lipoprotein(a).
Figure 1. Box plots with the 10th, 25th, 50th, 75th and 90th
percentiles. The serum Lp(a) level was significantly higher in the
stenosis group than in the Control and Spasm groups. The level
was also significantly higher in the Spasm group than in the
Control group. Control 5 control subjects without coronary artery
disease. Spasm 5 patients with coronary spasm but without a
significant fixed coronary stenosis. Stenosis 5 patients with a
significant fixed coronary stenosis but without rest angina; m 5
median.
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patients with, and those without, higher (.25 mg/dl) serum
Lp(a) level. As shown in Table 4, the incidence of patients
with higher levels of Lp(a) (.25 mg/dl) was significantly
greater in the patients with, than in those without, prior MI
in the Spasm group (56% vs. 21%, p , 0.05). However, this
was not the case in the Stenosis group. When the incidence
of prior MI was compared between the patients with higher
(.25 mg/dl) and lower (#25 mg/dl) levels of serum Lp(a)
in each group, a significantly greater incidence of prior MI
was noted in patients with higher, than in those with lower,
serum Lp(a) level in the Spasm group (41% vs. 13%, p ,
0.05), but not in the Stenosis group (Table 5).
Multivariate analysis. Multiple logistic regression analysis,
including age, gender, hypertension, smoking, body mass
index, diabetes mellitus and lipid variables (total, LDL and
HDL cholesterol, triglycerides and Lp[a]) was performed to
define the presence of prior MI. When all patients in the
Spasm group were included in this analysis, Lp(a) concen-
tration .25 mg/dl was the only variable independently
predictive for prior MI (odds ratio, 4.19; 95%, confidence
interval, 1.03 to 17.00; p , 0.05).
DISCUSSION
Relation between Lp(a) levels and prior MI in patients
with coronary spasm. It has been well documented that
plasma levels of Lp(a) vary widely between individuals in a
population while remaining remarkably constant through-
out life in a given individual (19). Lipoprotein(a) has been
shown to be an independent risk factor for atherosclerosis of
coronary and cerebral arteries (17,18). In the present study,
a significantly elevated serum Lp(a) level was confirmed in
patients with a significant fixed coronary artery stenosis.
Also, on the whole, the serum Lp(a) level of patients with
coronary spasm, but without significant fixed stenosis, was
Table 4. Comparison of the Incidence of Patients With Higher
(.25 mg/dl) Serum Level of Lipoprotein(a) in Study Patients








Spasm 61 13 (21%) p , 0.05 16 9 (56%)
Stenosis 63 25 (41%) NS 114 55 (48%)
Lp(a) 5 lipoprotein(a).
Table 3. Comparative Data of Risk Factors and Serum Lipid




No. of patients 61 16
Age (yr) 57 6 11 57 6 13
Male/female 52/9 13/3
Smoking 52 (85%) 13 (81%)
Hypertension 27 (44%) 4 (25%)
Hypercholesterolemia 13 (21%) 2 (13%)
Diabetes mellitus 11 (18%) 2 (13%)
Body mass index .25 15 (25%) 3 (19%)
Total cholesterol (mg/dl) 192 6 39 183 6 37
Triglyceride (mg/dl) 129 6 69 98 6 29
LDL cholesterol (mg/dl) 126 6 36 123 6 36
HDL cholesterol (mg/dl) 40 6 11 40 6 12
Lp(a)* (mg/dl) 16 (10–23) p , 0.05 29 (16–38)
*Median (interquartile range).
HDL 5 high-density lipoprotein; LDL 5 low-density lipoproein; Lp(a) 5
lipoprotein(a).
Figure 2. Box plots with the 10th, 25th, 50th, 75th and 90th
percentiles. The serum Lp(a) level was significantly higher in
patients with than in those without a history of previous myocar-
dial infarction among the Spasm group. Spasm 5 patients with
coronary spasm but without a significant fixed coronary stenosis.
MI 5 previous myocardial infarction; m 5 median.
Figure 3. Box plots with the 10th, 25th, 50th, 75th and 90th
percentiles. The serum Lp(a) level was not significantly different
between patients with and without a history of previous myocardial
infarction among the Stenosis group. Stenosis 5 patients with a
significant fixed coronary stenosis but without rest angina. MI 5
previous myocardial infarction; m 5 median.
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significantly higher than that found in the control subjects.
Most of our patients with vasospasm had a mild stenosis or
irregularity in the coronary arteries. However, the incidence
of subjects with higher serum Lp(a) levels (.25 mg/dl) was
found to be not significantly different between the patients
with coronary spasm and the control patients, suggesting
that it is difficult to discriminate by serum Lp(a) levels
between subjects with, and those without, coronary artery
spasm. The incidence was significantly greater in the pa-
tients with a significant fixed coronary stenosis than in
either the control subjects or the patients with coronary
spasm. Thus, the relation of elevated serum Lp(a) levels to
coronary spasm appears to be weak, if any. By contrast, the
incidence of subjects with higher serum Lp(a) levels (.25
mg/dl) was found to be significantly different between the
patients with, and those without, previous MI among
patients with coronary spasm. Coronary spastic patients
with prior MI had a significantly higher level of serum Lp(a)
than those without prior MI. The incidence of no other
convenient risk factors differed between patients with, and
those without, prior MI. Also in patients with coronary
vasospasm, a significantly higher incidence of prior MI was
noted in the subgroup with, than in the subgroup without,
serum levels of Lp(a) higher than 25 mg/dl. These results
indicate that an elevated serum level of Lp(a) is a risk factor for
the occurrence of acute MI in patients with coronary vaso-
spasm. The multivariate analysis confirmed that serum Lp(a)
level is an independent determinant for prior MI in patients
with coronary spasm.
Possible mechanisms of AMI in patients with high Lp(a)
levels. It is now established that intracoronary thrombus
formation is usually an essential event in the pathogenesis of
AMI (14). Coronary artery spasm is known to play an
important role in the occurrence of AMI in some patients
(17,18). It is not known whether coronary spasm, in itself,
can cause sufficiently severe and prolonged ischemia to
precipitate AMI or whether coronary spasm may predispose
to the formation of fibrin or platelet aggregates, which then
leads to prolonged total coronary obstruction and subse-
quent AMI. It is reported that the coagulation system was
activated after coronary spasm (5,26). However, turnover of
thrombus depends not only on formation but also on lysis.
Recently impaired fibrinolytic activity was demonstrated in
patients with variant angina (6,7). Both plasma plasminogen
activator inhibitor (PAI) activity and t-PA antigen concen-
trations were found to be significantly higher in patients
with variant angina than in patients with stable effort angina
or the control subjects (7). The main component of the
fibrinolytic system is plasmin, which dissolves fibrin or
thrombus and which is converted from plasminogen by
t-PA. Fibrinolysis is initiated by the release of t-PA from
the endothelium (27). Thus, t-PA promotes fibrinolysis,
whereas its specific inhibitor, PAI, rapidly inhibits t-PA by
complexing it. It has been postulated that high concentra-
tions of Lp(a) may hinder fibrinolysis. In in vitro studies,
Lp(a) has been shown to interfere with several steps in the
fibrinolytic pathway, including the binding of plasminogen
to endothelial cells and platelets, plasminogen activation on
the endothelial surface and the lysis of platelet-rich thrombi,
the binding of plasminogen and t-PA to fibrin and the
binding of plasminogen to its activator (28–31). A similar
interaction may occur in vivo. A significant relation of Lp(a)
to infarct artery patency and also vein graft stenosis has been
reported, suggesting an impaired fibrinolytic system in
patients with higher Lp(a) levels (32,33). Thus, the struc-
tural similarity of Lp(a) and plasminogen may allow the
former to compete with the latter for cellular receptors,
fibrin and t-PA, thereby diminishing plasminogen activa-
tion, plasmin production and, ultimately, fibrinolysis. Even
though, following coronary artery spasm, the coagulation
system is activated and fibrinolytic system is inhibited,
resulting in initiation of thrombus formation, the throm-
botic coronary obstruction may not be completed if the
spasm is of short duration and fibrinolytic activity is re-
stored. By contrast, if the fibrinolytic activation is extremely
impaired by high concentrations of Lp(a), thrombotic oc-
clusion secondary to severe coronary spasm may be estab-
lished and persist for long enough to cause AMI in some
patients with coronary vasospasm. Then the occluded
infarct-related artery may become patent in these patients,
probably because of delayed fibrinolysis after resolved spasm.
An elevated Lp(a) level is associated with coronary artery
disease in most but not all studies, which has caused
investigators to disagree about its importance (34). High
Lp(a) levels have been shown to promote events in subjects
with other coronary risk factors (16,35). It is possible that
the significant elevation of Lp(a) in patients with coronary
vasospasm and prior MI might be acting synergistically with
one or more other risk factors to produce the infarction.
By contrast to the patients with coronary spasm, no
significant differences in serum Lp(a) levels were found
between patients having a fixed coronary stenosis with prior
MI and those without prior MI. The Lp(a) appears to play
no significant role in the evolution of AMI or thrombotic
occlusion following plaque rupture in the advanced stage of
atherosclerotic coronary artery disease, even if this lipopro-
tein may be an important risk factor for the development or
initiation of coronary atherosclerosis.
Table 5. Comparison of the Incidence of a History of Previous
MI in Patients With Higher (.25 mg/dl) and Lower Serum
Level of Lipoprotein(a) in Study Patients
Lp(a) Level (mg/dl)
>25 >25
n MI n MI
Spasm 55 7 (13%) p , 0.05 22 9 (41%)
Stenosis 96 55 (61%) NS 81 59 (68%)
Lp(a) 5 lipoprotein(a); MI 5 myocardial infarction.
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CONCLUSIONS
The incidence of elevated serum Lp(a) level was not
significantly different between patients with coronary vaso-
spasm and control subjects, suggesting that this lipoprotein
may not play an important role in the pathogenesis of
coronary spasm. However, among the patients with coro-
nary spasm, a significantly higher level of serum Lp(a) was
noted in patients with, than in those without, prior MI,
suggesting that Lp(a) is a risk factor for the occurrence of
AMI in patients with coronary vasospasm.
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